JUDICIALIZATION OF DRUGS FOR TREATMENT OF HEPATITIS C IN RIO GRANDE DO SUL STATE, BRAZIL

Detalhes bibliográficos
Autor(a) principal: Acosta Vinholes, Bonnia
Data de Publicação: 2021
Outros Autores: Thomasi Jahnke Botton, Letícia, Hirdes, Alice
Tipo de documento: preprint
Idioma: por
Título da fonte: SciELO Preprints
Texto Completo: https://preprints.scielo.org/index.php/scielo/preprint/view/3107
Resumo: This article aims to identify which reasons lead people to seek the Judiciary in order to obtain medication for the treatment of hepatitis C. This is a quantitative cross-sectional descriptive study where 235 judgements and lower court decisions rendered by the state of Rio Grande do Sul Court of Justice between the years of 2010 and 2020 were analyzed. The results show that the main reason why people turn to the judiciary in order to obtain medication for the treatment of hepatitis C is low-income, followed by the ones who do not fit the requirements of the Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections, lack of predictability in having the medicine in the public list, zeroed stock and when the required medicine is not in ANVISA list. The results also pointed that the health judicialization is not a phenomenon connected to low-income; that the most required drugs are Ribavirina, Interferon, Sofosbuvir and Daclatasvir; that the percentage of judicial medicine concession is 93,6%. The data obtained lead to the conclusion that there is a need to reassess the Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections, the National Plan for Viral Hepatitis and the Plan for the Elimination of Hepatitis C.  
id SCI-1_dd43dcd4f7627033e6e93695db863d03
oai_identifier_str oai:ops.preprints.scielo.org:preprint/3107
network_acronym_str SCI-1
network_name_str SciELO Preprints
repository_id_str
spelling JUDICIALIZATION OF DRUGS FOR TREATMENT OF HEPATITIS C IN RIO GRANDE DO SUL STATE, BRAZILJUDICIALIZACIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO DE LA HEPATITIS C EN EL ESTADO DE RIO GRANDE DO SUL, BRASILJUDICIALIZAÇÃO DE MEDICAMENTOS PARA TRATAMENTO DA HEPATITE C NO ESTADO DO RIO GRANDE DO SUL, BRASILJudicialização da saúdePolítica públicaAssistência farmacêuticaHepatite CSistemas de SaúdeHealth judicializationPublic PolicyPharmaceutical ServicesHepatitis CHealth SystemsJudicialización de la SaludPolítica PúblicaServícios FarmacêuticosHepatitis CSistemas de SaludThis article aims to identify which reasons lead people to seek the Judiciary in order to obtain medication for the treatment of hepatitis C. This is a quantitative cross-sectional descriptive study where 235 judgements and lower court decisions rendered by the state of Rio Grande do Sul Court of Justice between the years of 2010 and 2020 were analyzed. The results show that the main reason why people turn to the judiciary in order to obtain medication for the treatment of hepatitis C is low-income, followed by the ones who do not fit the requirements of the Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections, lack of predictability in having the medicine in the public list, zeroed stock and when the required medicine is not in ANVISA list. The results also pointed that the health judicialization is not a phenomenon connected to low-income; that the most required drugs are Ribavirina, Interferon, Sofosbuvir and Daclatasvir; that the percentage of judicial medicine concession is 93,6%. The data obtained lead to the conclusion that there is a need to reassess the Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections, the National Plan for Viral Hepatitis and the Plan for the Elimination of Hepatitis C.  Este estudio tiene como objetivo identificar las razones que llevaron a las personas a acudir al Poder Judicial para obtener medicamentos para el tratamiento de la hepatitis C. Se trata de un estudio descriptivo transversal, de carácter cuantitativo, en el que se analizaron 235 juicios y decisiones. Decisiones dictadas por la Corte de Justicia del Estado de Rio Grande do Sul entre los años de 2010 y 2020. Resultados: se constató que la principal razón por la que las personas recurren al Poder Judicial para obtener medicamentos para el tratamiento de la hepatitis C es la insuficiencia de ingresos, seguida del incumplimiento de los requisitos del Protocolo Clínico y Guías Terapéuticas para Hepatitis C y co-infecciones, falta de provisión en la lista pública de medicamentos con existencia cero y medicamentos requeridos sin registro en ANVISA. Los resultados también mostraron que la judicialización de la salud no es un fenómeno restringido a las personas de bajos ingresos; que los medicamentos más requeridos son Ribavirin, Interferon, Sofosbuvir y Daclatasvir; que el porcentaje de otorgamiento judicial de medicamentos es de 93,6%. Los datos obtenidos llevan a concluir que es necesario reevaluar el Protocolo Clínico y Directrices Terapéuticas de Hepatitis C y Coinfecciones, el Plan Nacional de Hepatitis Virales y el Plan de Eliminación de Hepatitis C.    O artigo tem por objetivo identificar quais motivos levaram as pessoas a buscarem o Poder Judiciário, a fim de obter medicamentos para tratamento da hepatite C. Trata-se de um estudo descritivo transversal, de natureza quantitativa, no qual foram analisados 235 acórdãos e decisões monocráticas proferidas pelo Tribunal de Justiça do Estado do Rio Grande do Sul entre os anos de 2010 e 2020.  Os resultados evidenciam que o principal motivo pelo qual as pessoas recorrem ao Judiciário a fim de obter medicamentos para tratamento da hepatite C é a insuficiência de renda, seguido pelo não atendimento aos requisitos do Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções, ausência de previsão em lista pública de medicamentos, estoque zerado e medicamento requerido sem registro na ANVISA. Os resultados também apontaram que a judicialização da saúde não é um fenômeno adstrito às pessoas de baixa renda; os medicamentos mais requeridos são a Ribavirina, o Interferon, o Sofosbuvir e o Daclatasvir; o percentual de concessão judicial de medicamentos é de 93,6%. Os dados obtidos levam à conclusão de que há necessidade de reavaliação do Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções, do Plano Nacional de Hepatites Virais e do Plano para Eliminação da hepatite C.SciELO PreprintsSciELO PreprintsSciELO Preprints2021-11-04info:eu-repo/semantics/preprintinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://preprints.scielo.org/index.php/scielo/preprint/view/310710.1590/SciELOPreprints.3107porhttps://preprints.scielo.org/index.php/scielo/article/view/3107/5618Copyright (c) 2021 Bonnia Acosta Vinholes, Letícia Thomasi Jahnke Botton, Alice Hirdeshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessAcosta Vinholes, BonniaThomasi Jahnke Botton, LetíciaHirdes, Alicereponame:SciELO Preprintsinstname:SciELOinstacron:SCI2021-10-25T20:51:59Zoai:ops.preprints.scielo.org:preprint/3107Servidor de preprintshttps://preprints.scielo.org/index.php/scieloONGhttps://preprints.scielo.org/index.php/scielo/oaiscielo.submission@scielo.orgopendoar:2021-10-25T20:51:59SciELO Preprints - SciELOfalse
dc.title.none.fl_str_mv JUDICIALIZATION OF DRUGS FOR TREATMENT OF HEPATITIS C IN RIO GRANDE DO SUL STATE, BRAZIL
JUDICIALIZACIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO DE LA HEPATITIS C EN EL ESTADO DE RIO GRANDE DO SUL, BRASIL
JUDICIALIZAÇÃO DE MEDICAMENTOS PARA TRATAMENTO DA HEPATITE C NO ESTADO DO RIO GRANDE DO SUL, BRASIL
title JUDICIALIZATION OF DRUGS FOR TREATMENT OF HEPATITIS C IN RIO GRANDE DO SUL STATE, BRAZIL
spellingShingle JUDICIALIZATION OF DRUGS FOR TREATMENT OF HEPATITIS C IN RIO GRANDE DO SUL STATE, BRAZIL
Acosta Vinholes, Bonnia
Judicialização da saúde
Política pública
Assistência farmacêutica
Hepatite C
Sistemas de Saúde
Health judicialization
Public Policy
Pharmaceutical Services
Hepatitis C
Health Systems
Judicialización de la Salud
Política Pública
Servícios Farmacêuticos
Hepatitis C
Sistemas de Salud
title_short JUDICIALIZATION OF DRUGS FOR TREATMENT OF HEPATITIS C IN RIO GRANDE DO SUL STATE, BRAZIL
title_full JUDICIALIZATION OF DRUGS FOR TREATMENT OF HEPATITIS C IN RIO GRANDE DO SUL STATE, BRAZIL
title_fullStr JUDICIALIZATION OF DRUGS FOR TREATMENT OF HEPATITIS C IN RIO GRANDE DO SUL STATE, BRAZIL
title_full_unstemmed JUDICIALIZATION OF DRUGS FOR TREATMENT OF HEPATITIS C IN RIO GRANDE DO SUL STATE, BRAZIL
title_sort JUDICIALIZATION OF DRUGS FOR TREATMENT OF HEPATITIS C IN RIO GRANDE DO SUL STATE, BRAZIL
author Acosta Vinholes, Bonnia
author_facet Acosta Vinholes, Bonnia
Thomasi Jahnke Botton, Letícia
Hirdes, Alice
author_role author
author2 Thomasi Jahnke Botton, Letícia
Hirdes, Alice
author2_role author
author
dc.contributor.author.fl_str_mv Acosta Vinholes, Bonnia
Thomasi Jahnke Botton, Letícia
Hirdes, Alice
dc.subject.por.fl_str_mv Judicialização da saúde
Política pública
Assistência farmacêutica
Hepatite C
Sistemas de Saúde
Health judicialization
Public Policy
Pharmaceutical Services
Hepatitis C
Health Systems
Judicialización de la Salud
Política Pública
Servícios Farmacêuticos
Hepatitis C
Sistemas de Salud
topic Judicialização da saúde
Política pública
Assistência farmacêutica
Hepatite C
Sistemas de Saúde
Health judicialization
Public Policy
Pharmaceutical Services
Hepatitis C
Health Systems
Judicialización de la Salud
Política Pública
Servícios Farmacêuticos
Hepatitis C
Sistemas de Salud
description This article aims to identify which reasons lead people to seek the Judiciary in order to obtain medication for the treatment of hepatitis C. This is a quantitative cross-sectional descriptive study where 235 judgements and lower court decisions rendered by the state of Rio Grande do Sul Court of Justice between the years of 2010 and 2020 were analyzed. The results show that the main reason why people turn to the judiciary in order to obtain medication for the treatment of hepatitis C is low-income, followed by the ones who do not fit the requirements of the Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections, lack of predictability in having the medicine in the public list, zeroed stock and when the required medicine is not in ANVISA list. The results also pointed that the health judicialization is not a phenomenon connected to low-income; that the most required drugs are Ribavirina, Interferon, Sofosbuvir and Daclatasvir; that the percentage of judicial medicine concession is 93,6%. The data obtained lead to the conclusion that there is a need to reassess the Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections, the National Plan for Viral Hepatitis and the Plan for the Elimination of Hepatitis C.  
publishDate 2021
dc.date.none.fl_str_mv 2021-11-04
dc.type.driver.fl_str_mv info:eu-repo/semantics/preprint
info:eu-repo/semantics/publishedVersion
format preprint
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://preprints.scielo.org/index.php/scielo/preprint/view/3107
10.1590/SciELOPreprints.3107
url https://preprints.scielo.org/index.php/scielo/preprint/view/3107
identifier_str_mv 10.1590/SciELOPreprints.3107
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://preprints.scielo.org/index.php/scielo/article/view/3107/5618
dc.rights.driver.fl_str_mv Copyright (c) 2021 Bonnia Acosta Vinholes, Letícia Thomasi Jahnke Botton, Alice Hirdes
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Bonnia Acosta Vinholes, Letícia Thomasi Jahnke Botton, Alice Hirdes
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SciELO Preprints
SciELO Preprints
SciELO Preprints
publisher.none.fl_str_mv SciELO Preprints
SciELO Preprints
SciELO Preprints
dc.source.none.fl_str_mv reponame:SciELO Preprints
instname:SciELO
instacron:SCI
instname_str SciELO
instacron_str SCI
institution SCI
reponame_str SciELO Preprints
collection SciELO Preprints
repository.name.fl_str_mv SciELO Preprints - SciELO
repository.mail.fl_str_mv scielo.submission@scielo.org
_version_ 1797047825645699072

Registros relacionados